Frank Fan | CSO and Founder
Nanjing Legend Biotech

Frank Fan, CSO and Founder, Nanjing Legend Biotech

Dr. Fan is the co-founder of Legend Biotech and currently serves the company as the Chief Scientific Officer. Dr. Fan received his medical degree at Xi?an Jiaotong University in 1993 and worked as a surgical resident in the kidney Transplantation Centre of the university before he pursued his Ph.D. in applied immunology at Hiroshima University, Japan. He completed his postdoctoral training at the Hospital for Sick Children, University of Toronto, Canada where he became recognized as an expert in the field of the mechanism of human B cell tolerance. Dr. Fan has been published in numerous peer-reviewed academic journals, including an original article published in Nature Medicine which contribute to a revision in the clinical guidelines of pediatric organ transplantation. Dr. Fan?s scientific achievement paved the way by showing that small children can be safely transplanted with ABO blood group mismatched organs, and saved many lives of infant patients. Dr. Fan was awarded the ? New Key Opinion Leader ? award by The Transplantation Society in 2006. With the aid of GenScript, Dr. Fan co-founded Legend Biotech in 2015 and the company grew into a global leader in cancer immunotherapy in just 5 years. Citla-cel, a best-in-class BCMA-targeting CAR-T product Dr. Fan invented entered a global partnership with Janssen to co-develop the global markets. The product received breakthrough designation from the FDA and PRIME scheme from the EMA. Legend Biotech is now a Nasdaq listed company and BLA of Cilta-cel was already submitted. Dr. Fan is now leading the world?s largest cell therapy R&D team to develop more innovative technologies for treating solid tumors and other diseases.


Day 1: Wednesday 19th May 2021 - Cell Therapy @ 11:00

Clinical Progress & Global Competition in BCMA-targeted Immunotherapy

  • Multiple myeloma remain as an “incurable” cancer?
  • Clinical progress of CAR-T therapy in multiple myeloma
  • Competitive landscape of BCMA targeted therapy in early-stage commercial development
last published: 10/May/21 08:45 GMT

back to speakers